{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T10:22:40Z","timestamp":1780568560283,"version":"3.54.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,1,6]],"date-time":"2019-01-06T00:00:00Z","timestamp":1546732800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1007\/s00198-018-04820-8","type":"journal-article","created":{"date-parts":[[2019,1,6]],"date-time":"2019-01-06T05:54:02Z","timestamp":1546754042000},"page":"1111-1115","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Alendronate after denosumab discontinuation in women previously exposed to bisphosphonates was not effective in preventing the risk of spontaneous multiple vertebral fractures: two case reports"],"prefix":"10.1007","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3684-2376","authenticated-orcid":false,"given":"O.","family":"Lamy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Fern\u00e1ndez-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Monjo-Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Stoll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Aubry-Rozier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Benavent-N\u00fa\u00f1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Aguado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Gonzalez-Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,6]]},"reference":[{"key":"4820_CR1","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C, FREEDOM Trial (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756\u2013765","journal-title":"N Engl J Med"},{"key":"4820_CR2","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","volume":"5","author":"HG Bone","year":"2017","unstructured":"Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R, Cummings SR, Czerwi\u0144ski E, Fahrleitner-Pammer A, Kendler DL, Lippuner K, Reginster JY, Roux C, Malouf J, Bradley MN, Daizadeh NS, Wang A, Dakin P, Pannacciulli N, Dempster DW, Papapoulos S (2017) 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol 5:513\u2013523","journal-title":"Lancet Diabetes Endocrinol"},{"key":"4820_CR3","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1210\/jc.2010-1502","volume":"96","author":"HG Bone","year":"2011","unstructured":"Bone HG, Bolognese MA, Yuen CK, Kendler DL, Miller PD, Yang YC, Grazette L, San Martin J, Gallagher JC (2011) Effects of denosumab treatment and discontinuation on bone mineral density and bone turn-over markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab 96:972\u2013980","journal-title":"J Clin Endocrinol Metab"},{"key":"4820_CR4","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s00223-018-0394-4","volume":"103","author":"AW Popp","year":"2018","unstructured":"Popp AW, Varathan N, Buffat H, Senn C, Perrelet R, Lippuner K (2018) Bone mineral density changes after 1 year of denosumab discontinuation in postmenopausal women with long-term denosumab treatment for osteoporosis. Calcif Tissue Int 103:50\u201354. \n                    https:\/\/doi.org\/10.1007\/s00223-018-0394-4","journal-title":"Calcif Tissue Int"},{"key":"4820_CR5","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1210\/jc.2016-3170","volume":"102","author":"O Lamy","year":"2017","unstructured":"Lamy O, Stoll D, Gonzalez-Rodriguez E, Hans D, Aubry-Rozier B (2017) Severe rebound-associated vertebral fractures after denosumab discontinuation: nine clinical cases report. J Clin Endocrinol Metab 102:354\u2013358","journal-title":"J Clin Endocrinol Metab"},{"key":"4820_CR6","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1007\/s00198-017-3919-1","volume":"28","author":"MR McClung","year":"2017","unstructured":"McClung MR, Wagman RB, Miller PD, Wang A, Lewiecki EM (2017) Observations following discontinuation of long-term denosumab therapy. Osteoporos Int 28:1723\u20131732","journal-title":"Osteoporos Int"},{"key":"4820_CR7","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1002\/jbmr.3110","volume":"32","author":"AD Anastasilakis","year":"2017","unstructured":"Anastasilakis AD, Polyzos SA, Makras P, Aubry-Rozier B, Kaouri S, Lamy O (2017) Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases. J Bone Miner Res 32:1291\u20131296","journal-title":"J Bone Miner Res"},{"key":"4820_CR8","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/jbmr.3337","volume":"33","author":"SR Cummings","year":"2018","unstructured":"Cummings SR, Ferrari S, Eastell R, Gilchrist N, Jensen JEB, McClung M, Roux C, T\u00f6rring O, Valter I, Wang AT, Brown JP (2018) Vertebral fractures after discontinuation of Denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension. J Bone Miner Res 33:190\u2013198","journal-title":"J Bone Miner Res"},{"key":"4820_CR9","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1002\/jbmr.3370","volume":"33","author":"O Lamy","year":"2018","unstructured":"Lamy O, Gonzalez-Rodriguez E (2018) Underestimation of vertebral fractures after denosumab discontinuation. J Bone Miner Res 33:547","journal-title":"J Bone Miner Res"},{"key":"4820_CR10","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1002\/jbmr.3359","volume":"33","author":"B Leder","year":"2018","unstructured":"Leder B (2018) An essential warning: editorial on vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial, its extension. J Bone Miner Res 33:188\u2013189","journal-title":"J Bone Miner Res"},{"key":"4820_CR11","first-page":"w14484","volume":"147","author":"C Meier","year":"2017","unstructured":"Meier C, Uebelhart B, Aubry-Rozier B et al (2017) Osteoporosis drug treatment: duration and management after discontinuation. A position statement from the SVGO\/ASCO. Swiss Med Wkly 147:w14484","journal-title":"Swiss Med Wkly"},{"key":"4820_CR12","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.bone.2017.08.003","volume":"105","author":"E Tsourdi","year":"2017","unstructured":"Tsourdi E, Langdahl B, Cohen-Solal M, Aubry-Rozier B, Eriksen EF, Gua\u00f1abens N, Obermayer-Pietsch B, Ralston SH, Eastell R, Zillikens MC (2017) Discontinuation of denosumab therapy for osteoporosis: a systematic review and position statement by ECTS. Bone 105:11\u201317","journal-title":"Bone"},{"key":"4820_CR13","doi-asserted-by":"publisher","unstructured":"Tripto-Shkolnik L, Rouach V, Marcus Y, Rotman-Pikielny P, Benbassat C, Vered I (2018) Vertebral fractures following denosumab discontinuation in patients with prolonged exposure to bisphosphonates. Calcif Tissue Int. \n                    https:\/\/doi.org\/10.1007\/s00223-018-0389-1\n                    \n                  .","DOI":"10.1007\/s00223-018-0389-1"},{"key":"4820_CR14","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1530\/EJE-16-1027","volume":"176","author":"AD Anastasilakis","year":"2017","unstructured":"Anastasilakis AD, Yavropoulou MP, Makras P, Sakellariou GT, Papadopoulou F, Gerou S, Papapoulos SE (2017) Increased osteoclastogenesis in patients with vertebral fractures following discontinuation of denosumab treatment. Eur J Endocrinol 176:677\u2013683","journal-title":"Eur J Endocrinol"},{"key":"4820_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/5432751","volume":"5432751","author":"E Gonzalez-Rodriguez","year":"2018","unstructured":"Gonzalez-Rodriguez E, Stoll D, Lamy O (2018) Raloxifene has no efficacy in reducing the high bone turnover and the risk of spontaneous vertebral fractures after denosumab discontinuation. Case Rep Rheumatol 5432751:1\u20134. \n                    https:\/\/doi.org\/10.1155\/2018\/5432751","journal-title":"Case Rep Rheumatol"},{"key":"4820_CR16","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s00223-017-0288-x","volume":"101","author":"IR Reid","year":"2017","unstructured":"Reid IR, Horne AM, Mihov B, Gamble GD (2017) Bone loss after denosumab: only partial protection with zoledronate. Calcif Tissue Int 101:371\u2013374","journal-title":"Calcif Tissue Int"},{"key":"4820_CR17","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1359\/JBMR.040920","volume":"20","author":"CJ Rosen","year":"2005","unstructured":"Rosen CJ, Hochberg MC, Bonnick SL, McClung M, Miller P, Broy S, Kagan R, Chen E, Petruschke RA, Thompson DE, de Papp AE, Fosamax Actonel Comparison Trial Investigators (2005) Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. J Bone Miner Res 20:141\u2013151","journal-title":"J Bone Miner Res"},{"key":"4820_CR18","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1056\/NEJMoa011807","volume":"346","author":"IR Reid","year":"2002","unstructured":"Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U, Widmer A, Devogelaer JP, Kaufman JM, Jaeger P, Body JJ, Brandi ML, Broell J, di Micco R, Genazzani AR, Felsenberg D, Happ J, Hooper MJ, Ittner J, Leb G, Mallmin H, Murray T, Ortolani S, Rubinacci A, S\u00e4\u00e4f M, Samsioe G, Verbruggen L, Meunier PJ (2002) Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 346:653\u2013661","journal-title":"N Engl J Med"},{"key":"4820_CR19","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.1007\/s00198-017-4080-6","volume":"28","author":"B Uebelhart","year":"2017","unstructured":"Uebelhart B, Rizzoli R, Ferrari SL (2017) Retrospective evaluation of serum CTX levels after denosumab discontinuation in patients with or without prior exposure to bisphosphonates. Osteoporos Int 28:2701\u20132705","journal-title":"Osteoporos Int"},{"key":"4820_CR20","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s00223-018-0409-1","volume":"103","author":"AD Anastasilakis","year":"2018","unstructured":"Anastasilakis AD, Tournis S, Yavropoulou MP, Polyzos SA, Makras P (2018) Multiple vertebral fractures following denosumab discontinuation: are we exaggerating? Calcif Tissue Int 103:107\u2013108","journal-title":"Calcif Tissue Int"},{"key":"4820_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00223-018-0436-y","volume":"103","author":"E Tsourdi","year":"2018","unstructured":"Tsourdi E, Zillikens MC (2018) Certainties and uncertainties about denosumab discontinuation. Calcif Tissue Int 103:1\u20134","journal-title":"Calcif Tissue Int"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-018-04820-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-018-04820-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-018-04820-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,5]],"date-time":"2020-01-05T19:09:57Z","timestamp":1578251397000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-018-04820-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,6]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["4820"],"URL":"https:\/\/doi.org\/10.1007\/s00198-018-04820-8","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,6]]},"assertion":[{"value":"21 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}